六福彩票Ripretinib is a novel tyrosine kinase inhibitor that was designed to target KIT and PDGFRα-mutated kinase. A phase III study (INVICTUS) showed that ripretinib improved PFS and OS compared with placebo in patients with GIST progressed with more than three
2019 ESMO congress
六福彩票In phase 3 PAOLA-1 trial, olaparib plus bevacizumab as first-line maintenance therapy significantly prolongs the progression-free survival of ovarian cancer patients.
N Engl J Med & Annals of Oncology
The plasmaMATCH trial is a phase 2a, open-label, multicentre trial in patients with advanced breast cancer. The trial aims to evaluate whether certain genetic mutation identified through ctDNA could benefit patients from matched targeted treatments. In th
Wardley. SABCS 2019
六福彩票A study showed the mechanism of activating PI3K/AKT/mTOR signaling by double PIK3CA mutations in cis. Furthermore, a retrospective analysis of a phase III study (SANDPIPER) showed that co-occurring PIK3CA mutations were associated with clinical benefits i
六福彩票In phase 3 ClarIDHy trial, ivosidenib showed a strong efficacy in treating cholangiocarcinoma patients who had an IDH1 mutation. Ivosidenib extended both the OS and PFS significantly compared to the control group.
Annals of Oncology (2019)
六福彩票There is ongoing debate on which treatment is optimal for patients with advanced renal cell carcinoma. The phase II CABOSUN trial demonstrated cabozantinib improved response compared to sunitinib. The MET status was associated with greater benefit.
A phase III study (PROfound) showed that homologous recombination repair (HRR) gene mutations were associated with greater clinical benefits compared with physician’s choice of enzalutamide or abiraterone plus prednisone in heavily pretreated mCRPC patien
ESMO Congress 2019
In the phase 3 VELIA trial, veliparib showed a good therapeutic effect when added to standard first-line chemotherapy and continued as maintenance therapy in ovarian cancer.
六福彩票N Engl J Med. 2019
According to findings from the phase 2 FIGHT-202 clinical trial presented at ESMO 2019, pemigatinib, a selective inhibitor of FGFR1, 2, and 3, showed clinical benefits in previously treated advanced or metastatic cholangiocarcinoma (CCA) patients with an
六福彩票2019 ESMO Congress
六福彩票The results of a phase III study (MYSTIC) showed that ARID1A mutation were associated with clinical benefits in patients received durvalumab plus tremelimumab combination therapy